Development of lopinavir-loaded nanostructured lipid carriers combined with iontophoresis application for transdermal administration

Vol. 1, 2019. - 116733
Pôster
Favorite this paper
How to cite this paper?
Abstract

Lopinavir (LPV) is an antiretroviral drug used to control human immunodeficiency virus infection. Its low oral bioavailability, complex therapeutic regimen and adverse effects hampers therapy efficiency1. To do so, nanostructured lipid carriers containing LPV (CLN-LPV) were developed and drug electrical stability was verified prior to permeation studies. Lipid nanoparticles were composed with stearic acid, oleic acid, surfactants and different LPV content (0.5 to 1.5 mg/mL). Mean diameter increased with higher LPV content (p<0.05) (145.8 ± 5.2 to 179.0 ± 2.5 nm). Electrical stability of LPV (1mg/mL) was assessed and 92.4 ± 1.02% of drug recovery was achieved. Electrical stability of CLN-LPV demonstrated no drug degradation, but entrapment efficiency was decreased (to 87.03 ± 0.33% to 80.02 ± 0.79%). Iontophoresis significantly increased drug skin permeation compared to passive permeation (p<0.05). CLN-LPV combined with iontophoresis seems to be promising formulation for LPV transdermal delivery.

Institutions
  • 1 Faculdade de Farmácia / Universidade Federal de Goiás
  • 2 Universidade Federal de Goiás
Track
  • Nanotechnology
Keywords
transdermal administration
lopinavir
electric current